



TEVA PHARMACEUTICAL INDUSTRIES LTD.

Contact: Liraz Kalif / Kevin Mannix
Teva Investor Relations
(011) 972-3-926-7281 / (215) 591-8912

FOR IMMEDIATE RELEASE

**TEVA TO REPORT FOURTH QUARTER 2006 FINANCIAL RESULTS ON
FEBRUARY 13, 2007**

CONFERENCE CALL SCHEDULED FOR 8:45 AM ET

COMPANY TO HOST MARKETSITE EVENT ON FEBRUARY 21, 2007

Jerusalem, Israel, February 2, 2007 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter 2006 financial results on Tuesday, February 13, 2007. The earnings release will be available on Teva's web site at www.tevapharm.com.

Teva will host a conference call and live webcast on that same day, at 08:45 AM ET to discuss its fourth quarter 2006 results and overall business environment. A Question & Answer session will follow this discussion.

Investors and other interested parties may access a live webcast through Teva's web site at www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site. Alternatively, a replay of the call can be accessed until February 20, 2007 at 11:59 (ET), by calling 1-(201) 612-7415 outside the U.S. or 1-(877) 660-6853 in the U.S. The Pass Code to access the replay is: Account # 3055 and Conference ID# 229480.

Additionally, in lieu of the New York investor luncheon, Teva will host a reception on February 21, 2007 at the NASDAQ MarketSite to celebrate the Company's 25th listing anniversary on the NASDAQ stock exchange. Details will be provided at a later date.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80% of Teva's sales are in North America and Europe.